Tariff plan threatens supply chains
Reports say the U.S. will impose 100% tariffs on branded or patented pharmaceutical imports unless manufacturers build domestic production capacity, a move that could force rapid reshoring and change supply‑chain profiles. (worldpharmatoday.com) (pharmaceuticalcommerce.com).
On April 2, 2026, the White House signed an order that can levy tariffs of up to 100% on imported branded or patented pharmaceuticals and their ingredients as a tool to force more U.S. production. (whitehouse.gov) The tariff authority is grounded in a Commerce Department investigation under Section 232 of the Trade Expansion Act, which the administration says found that heavy reliance on foreign-made patented drugs threatens national security. (whitehouse.gov) The mechanics are straightforward on paper but complex in practice: imports from companies that do not sign “Most Favored Nation” (MFN) pricing deals or agree to onshoring terms could face the full 100% duty; firms that sign onshoring agreements would see tariffs cut to 20%; firms that both onshore and accept MFN pricing receive a 0% tariff—at least through January 20, 2029. (pharmexec.com) (bloomberg.com) The order also carves out countries that already have trade deals with the United States: products from the European Union, Japan, South Korea, Switzerland and Liechtenstein face a preferential 15% rate, and the U.K. receives a lower negotiated rate. The White House says certain product classes—generics, biosimilars, orphan drugs and some animal-health medicines—are exempt for now. (whitehouse.gov) (bloomberg.com) Drugmakers reacted quickly last year and since: several major firms struck MFN deals with the administration and pledged large U.S. manufacturing investments, which the White House now cites as roughly $400 billion in commitments. (fiercepharma.com) (whitehouse.gov) For safety and regulatory teams, the immediate consequence is operational: shifting production footprint requires Chemistry, Manufacturing, and Controls (CMC) notifications and, in many cases, prior-approval supplements to the FDA for site, process, or equipment changes—submissions that can trigger FDA inspections and extend timelines. (fda.gov) (ecfr.gov) Those procedural realities imply concrete downstream work for pharmacovigilance: new sites and suppliers can change impurity profiles, container-closure interactions, and other batch-level attributes that affect stability and adverse-event patterns; sponsors will need tighter lot-lineage mapping, enhanced signal stratification by manufacturing source, and comparability protocols to demonstrate no clinically meaningful change. (fda.gov) (jhu.edu) Regulatory risk also includes supply disruption. Analysts warn that rapid tariffs and hastened reshoring can create shortfalls while new plants come online, which would complicate recalls, replacement sourcing, and adverse-event follow-up during shortages. (cnbc.com) (supplychaindive.com) The order’s timelines are concrete: duties start on a phased basis—120 days for larger manufacturers and 180 days for smaller ones—giving commercial, regulatory and safety teams a short runway to complete site-change filings and contingency sourcing where needed. (whitehouse.gov) Genentech is among the companies that signed MFN agreements last year and therefore stands to keep tariff relief under the administration’s terms through January 20, 2029, provided onshoring commitments are met. (fiercepharma.com)
